TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04405102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: The investigational medical product (IMP) for this study is ozanimod. Ozanimod 0.23 mg be administered once daily for 4 days and then ozanimod 0.46 mg will be administered once daily for ten days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: During hospitalization, patient will be given standard of care (Recommendations for standard of care management of COVID-19 will be provided for anticoagulation, fluid resuscitation, corticoids and other immunomodulators, antipyretics agents, antiviral agents and other treatments. These recommendations are subject to modifications based on the new literature data).
Study: NCT03146156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: The lifestyle intervention is healthy eating (Medeterranian diet) and exercise to decrease weight by 5-7% compared to prepregnancy weight.
Study: NCT01592695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy - nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion Sustained Release
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01390584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: May be given orally, IV push, or by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procarbazine
Description: PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: PO
Study: NCT00066937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline Oral Capsule
Description: Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nortriptyline Oral Capsule
Description: Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benztropine Oral Product
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benztropine Oral Product
Description: Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease MGT
Description: Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disease MGT
Description: Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
Study: NCT02470767

Intervention type: DRUG
Intervention: Direct Oral Anticoagulant (DOAC)
Description: Treatment pattern following the summary of product characteristics
Study: NCT02623439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Description: Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
Study: NCT02382900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Description: dose scheme (0 and 6 month)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Description: dose scheme (0 and 6 month)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine
Description: dose scheme (0 and 6 month)
Study: NCT00250575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Study: NCT01592695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Sustained Release
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT02127060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: for 1 month postoperative period, vitamin C was administered orally to the patients.
Study: NCT01252888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStents
Description: Implantation of two iStents through a small temporal clear corneal incision
Study: NCT01592695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine gum
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination pharmacotherapy - transdermal nicotine patch + bupropion
Description: Medication selection will be determined based on individual participant preferences, medical history, and contraindications
Study: NCT01506375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 1 subcutaneous injection every 7 days during 29 days
Study: NCT01592695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol use risk reduction
Description: Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation for the treatment of depression
Description: Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
Study: NCT02127060

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: for 1 month postoperative period, placebo medication administered orally to the patients.
Study: NCT04441866

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Automated algorithms
Description: Automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
Study: NCT01592695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral management of post-cessation weight gain
Description: Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
Study: NCT03901599

Intervention type: OTHER
Intervention: Alveolar ventilation monitoring estimated by the capnographic ventilation
Description: Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.

Intervention type: OTHER
Intervention: Alveolar ventilation monitoring estimated by the capnographic ventilation
Description: Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.

Intervention type: OTHER
Intervention: Alveolar ventilation monitoring estimated by the capnographic ventilation
Description: Children are monitored using end-tidal CO2, Transcutaneous CO2 and volumetric capnographic. Respiratory rate is set using textbooks and guidelines (pediatric advanced life support). The physician in charge adapts the volume to target a CO2 between 38 and 42 mmHg. Data are recorded after a stabilization period of at least 5 minutes.
Study: NCT01506375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM + adjuvant
Description: 1 subcutaneous injection every 7 days during 29 days
Study: NCT01236807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR perfusion guidance
Description: Coronary revascularization guided by MR perfusion imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guidance
Description: Coronary revascularization guided by invasive angiography and FFR
Study: NCT03397758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study population
Description: First, periorbital area was treated with the short needles (exposure time 150ms, power 9W) to tighten the overlying dermis. Then, the fat pocket itself was treated additionally with the long needle (exposure time 400ms, power 9W).
Study: NCT03599466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BF-Lisinopril Tablets 20mg
Description: BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF-Lisinopril Tablets 20mg
Description: BF-Lisinopril Tablets 20mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zestril Tab 20mg
Description: Zestril Tab 20mg will be used as a reference drug in this study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestril Tab 20mg
Description: Zestril Tab 20mg will be used as a reference drug in this study
Study: NCT03517293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise training
Study: NCT03028922

Intervention type: DEVICE
Group type: OTHER
Intervention: creos xenogain
Description: GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
Study: NCT03061214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin placebo
Description: Sitagliptin placebo tablets taken once-daily for 30 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin placebo
Description: Sitagliptin placebo tablets taken once-daily for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin tablets taken once-daily for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin tablets taken once-daily for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide placebo 0.5 mg
Description: Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide placebo 1.0 mg
Description: Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
Study: NCT02427672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study: NCT00967174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study: NCT01348490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib (INCB018424), 5 mg bid
Study: NCT01623154

Intervention type: OTHER
Group type: OTHER
Intervention: Pranactin citric solution
Description: All patients were required to drink the pranactic citric solution to diagnose H.pylori.
Study: NCT00967174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS Comparator Patch
Description: 0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study: NCT03874780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibe Delivery system
Description: delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
Study: NCT00641849

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
Study: NCT04084782

Intervention type: DEVICE
Intervention: Fungal Nail Treatment Kit
Description: The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
Study: NCT04916899

Intervention type: DRUG
Intervention: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol
Description: Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
Study: NCT03912480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells from human exfoliated teeth
Description: Intravenous infusion of pulp mesenchymal stem cells
Study: NCT00356486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a, Ribavirin, epoetin-β
Description: Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + Ribavirin for 12 weeks
Description: Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
Study: NCT02771210

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab Placebo
Description: Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
Study: NCT03316612

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vaccinium Myrtillus L. extract
Description: Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study: NCT02035215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acids ethylesters 90 4g

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Omega-3-acids ethylesters 90)
Study: NCT03875547

Intervention type: DRUG
Intervention: Refixia®
Description: Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
Study: NCT06437691

Intervention type: PROCEDURE
Intervention: Self-Expandable Metallic Stent Placement
Study: NCT04292548

Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine TAS, TOS and LL-37

Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine TAS, TOS and LL-37
Study: NCT00538031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study: NCT04042233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Intraosseous vancomycin 500mg in 250 mL NS
Description: 500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV administration of vancomycin
Description: IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
Study: NCT01894802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CRS Arrays
Description: Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
Study: NCT04018768

Intervention type: OTHER
Intervention: ibuprofen 600 mg
Description: MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.

Intervention type: OTHER
Intervention: Oxycodone/acetaminophen (Percocet) 5 mg/325
Description: MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.

Intervention type: OTHER
Intervention: Oxycodone/acetaminophen (Percocet) 5 mg/325
Description: MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
Study: NCT04168411

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic Treatment
Description: Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptomatic Treatment
Description: Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
Study: NCT03068520

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET MR
Description: PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
Study: NCT00098631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00815308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux)
Description: Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
Study: NCT01633060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 100 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BKM120 matching placebo
Description: BKM120 matching placebo, once daily